Terms: = Prostate cancer AND LEF1, TCF1ALPHA, 51176, ENSG00000138795, Q9UJU2, DKFZp586H0919
21 results:
1. DCUN1D1 Is an Essential Regulator of prostate cancer Proliferation and Tumour Growth That Acts through Neddylation of Cullin 1, 3, 4A and 5 and Deregulation of Wnt/Catenin Pathway.
Vava A; Paccez JD; Wang Y; Gu X; Bhasin MK; Myers M; Soares NC; Libermann TA; Zerbini LF
Cells; 2023 Jul; 12(15):. PubMed ID: 37566052
[TBL] [Abstract] [Full Text] [Related]
2. cancer-derived exosomal miR-375 targets DIP2C and promotes osteoblastic metastasis and prostate cancer progression by regulating the Wnt signaling pathway.
Liu Y; Yang C; Chen S; Liu W; Liang J; He S; Hui J
Cancer Gene Ther; 2023 Mar; 30(3):437-449. PubMed ID: 36434177
[TBL] [Abstract] [Full Text] [Related]
3. Wnt/β-catenin signaling contributes to prostate cancer heterogeneity through reciprocal suppression of H3K27 trimethylation.
Wang F; Zhu Y; Wang F; Wang Y; Dong BJ; Wang N; Gao WQ
Biochem Biophys Res Commun; 2020 Jun; 527(1):242-249. PubMed ID: 32446375
[TBL] [Abstract] [Full Text] [Related]
4. m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified lef1.
Ma XX; Cao ZG; Zhao SL
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3565-3571. PubMed ID: 32329830
[TBL] [Abstract] [Full Text] [Related]
5. DNA-Dependent Protein Kinase Drives prostate cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.
Kothari V; Goodwin JF; Zhao SG; Drake JM; Yin Y; Chang SL; Evans JR; Wilder-Romans K; Gabbara K; Dylgjeri E; Chou J; Sun G; Tomlins SA; Mehra R; Hege K; Filvaroff EH; Schaeffer EM; Karnes RJ; Quigley DA; Rathkopf DE; He HH; Speers C; Spratt DE; Gilbert LA; Ashworth A; Chinnaiyan AM; Raj GV; Knudsen KE; Feng FY
Clin Cancer Res; 2019 Sep; 25(18):5608-5622. PubMed ID: 31266829
[TBL] [Abstract] [Full Text] [Related]
6. Long noncoding RNA lef1-AS1 silencing suppresses the initiation and development of prostate cancer by acting as a molecular sponge of miR-330-5p via lef1 repression.
Liu DC; Song LL; Liang Q; Hao L; Zhang ZG; Han CH
J Cell Physiol; 2019 Aug; 234(8):12727-12744. PubMed ID: 30613973
[TBL] [Abstract] [Full Text] [Related]
7. MicroRNA-34a Attenuates Paclitaxel Resistance in prostate cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
[TBL] [Abstract] [Full Text] [Related]
8. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review).
Katoh M
Int J Mol Med; 2018 Aug; 42(2):713-725. PubMed ID: 29786110
[TBL] [Abstract] [Full Text] [Related]
9. Role of miR-452-5p in the tumorigenesis of prostate cancer: A study based on the cancer Genome Atl(TCGA), Gene Expression Omnibus (GEO), and bioinformatics analysis.
Gao L; Zhang LJ; Li SH; Wei LL; Luo B; He RQ; Xia S
Pathol Res Pract; 2018 May; 214(5):732-749. PubMed ID: 29559248
[TBL] [Abstract] [Full Text] [Related]
10. prostate apoptosis response 4 (PAR4) expression modulates WNT signaling pathways in MCF7 breast cancer cells: A possible mechanism underlying PAR4-mediated docetaxel chemosensitivity.
de Bessa Garcia SA; Pavanelli AC; Cruz E Melo N; Nagai MA
Int J Mol Med; 2017 Apr; 39(4):809-818. PubMed ID: 28259909
[TBL] [Abstract] [Full Text] [Related]
11. Expression and colocalization of β-catenin and lymphoid enhancing factor-1 in prostate cancer progression.
Bauman TM; Vezina CM; Ricke EA; Halberg RB; Huang W; Peterson RE; Ricke WA
Hum Pathol; 2016 May; 51():124-33. PubMed ID: 27067790
[TBL] [Abstract] [Full Text] [Related]
12. EphB4 localises to the nucleus of prostate cancer cells.
Mertens-Walker I; Lisle JE; Nyberg WA; Stephens CR; Burke L; Rutkowski R; Herington AC; Stephenson SA
Exp Cell Res; 2015 Apr; 333(1):105-15. PubMed ID: 25724901
[TBL] [Abstract] [Full Text] [Related]
13. lef1 Targeting EMT in prostate cancer Invasion Is Regulated by miR-34a.
Liang J; Li Y; Daniels G; Sfanos K; De Marzo A; Wei J; Li X; Chen W; Wang J; Zhong X; Melamed J; Zhao J; Lee P
Mol Cancer Res; 2015 Apr; 13(4):681-8. PubMed ID: 25587085
[TBL] [Abstract] [Full Text] [Related]
14. Normoxic or hypoxic CD44/CD41 a₂ B₁ integrin-positive prostate PC3 cell side fractions and cancer stem cells.
Anderson KM; Guinan P; Rubenstein M
Med Oncol; 2014 Jan; 31(1):779. PubMed ID: 24323398
[TBL] [Abstract] [Full Text] [Related]
15. ERG is a critical regulator of Wnt/lef1 signaling in prostate cancer.
Wu L; Zhao JC; Kim J; Jin HJ; Wang CY; Yu J
Cancer Res; 2013 Oct; 73(19):6068-79. PubMed ID: 23913826
[TBL] [Abstract] [Full Text] [Related]
16. Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models.
Becker-Santos DD; Guo Y; Ghaffari M; Vickers ED; Lehman M; Altamirano-Dimas M; Oloumi A; Furukawa J; Sharma M; Wang Y; Dedhar S; Cox ME
Carcinogenesis; 2012 Dec; 33(12):2558-67. PubMed ID: 23027626
[TBL] [Abstract] [Full Text] [Related]
17. Biochemical control with radiotherapy improves overall survival in intermediate and high-risk prostate cancer patients who have an estimated 10-year overall survival of >90%.
Herbert C; Liu M; Tyldesley S; Morris WJ; Joffres M; Khaira M; Kwan W; Moiseenko V; Pickles T
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):22-7. PubMed ID: 22079724
[TBL] [Abstract] [Full Text] [Related]
18. Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway.
Hsieh TH; Tsai CF; Hsu CY; Kuo PL; Lee JN; Chai CY; Wang SC; Tsai EM
FASEB J; 2012 Feb; 26(2):778-87. PubMed ID: 22049059
[TBL] [Abstract] [Full Text] [Related]
19. PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/lef1low increase tumor angiogenesis.
Zhang K; Waxman DJ
Mol Cancer; 2010 Dec; 9():319. PubMed ID: 21190562
[TBL] [Abstract] [Full Text] [Related]
20. lef1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion.
Li Y; Wang L; Zhang M; Melamed J; Liu X; Reiter R; Wei J; Peng Y; Zou X; Pellicer A; Garabedian MJ; Ferrari A; Lee P
Cancer Res; 2009 Apr; 69(8):3332-8. PubMed ID: 19351848
[TBL] [Abstract] [Full Text] [Related]
[Next]
